SUPN Stock: Price, Earnings History and SEC Filings
Supernus Pharmaceuticals, Inc. (SUPN) last traded at $41.92, up 0.19% on the latest session and down 2.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.78 against an analyst estimate of $0.34, a beat of 129.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SUPN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.78 | $0.34 | +129.41% |
| Jun 2026 | Aug 3, 2026 | $0.39 | $0.30 | +30.00% |
| Mar 2026 | May 5, 2026 | $0.45 | $0.14 | +221.43% |
| Dec 2025 | Feb 24, 2026 | $0.75 | $0.14 | +435.71% |
SUPN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How SUPN reacts to earnings
Across its last 8 earnings releases, SUPN moved 2.5% on average the next session, in either direction. It rose after 8 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | +0.19% |
| 2026-10-19 | After close | +3.49% |
| 2026-08-03 | Before open | +3.07% |
| 2026-07-22 | After close | +0.53% |
| 2026-05-05 | After close | +4.59% |
| 2026-04-22 | After close | +0.20% |
| 2026-02-24 | After close | +5.67% |
| 2026-02-12 | After close | +1.99% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SUPN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $719M | -$39M | $46M | -5.4% | $-0.68 |
| 2024 | $662M | $74M | $171M | 11.2% | $1.32 |
| 2023 | $608M | $1M | $111M | 0.2% | $0.02 |
| 2022 | $667M | $61M | $116M | 9.1% | $1.04 |
| 2021 | $580M | $53M | – | 9.2% | $0.98 |
| 2020 | $520M | $127M | $135M | 24.4% | $2.36 |
| 2019 | $393M | $113M | $140M | 28.8% | $2.10 |
| 2018 | $409M | $111M | $128M | 27.1% | $2.05 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SUPN
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 26, 2026Agreement terminated, Financial statements and exhibits
- 8-K · Oct 22, 2026Other events, Financial statements and exhibits
- 8-K · Oct 19, 2026Results of operations
- 8-K · Oct 15, 2026Shareholder vote, Financial statements and exhibits
- 8-K · Aug 3, 2026Other events, Financial statements and exhibits
- 8-K · Aug 3, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
Insider filing activity
SUPN insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SUPN news
- SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior mergerNov 1, 2026 · finance.yahoo.com
- Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround NarrativeOct 30, 2026 · finance.yahoo.com
- Supernus (SUPN) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third QuarterOct 30, 2026 · finance.yahoo.com
- Supernus Pharmaceuticals Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Supernus: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (SUPN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.